World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
31021
World Ranking
14957
National Ranking
788

Overview

Andreas du Bois is affiliated with Johannes Gutenberg University of Mainz in Germany. Their research primarily focuses on ovarian cancer diagnosis and treatment within the broader fields of Medicine as well as Biochemistry, Genetics and Molecular Biology. Their work spans several subfields such as Reproductive Medicine, Obstetrics and Gynecology, Oncology, Cancer Research, and Genetics.

The main topics addressed in their research include:

  • Ovarian cancer diagnosis and treatment
  • Endometrial and Cervical Cancer Treatments
  • PARP inhibition in cancer therapy
  • Intraperitoneal and Appendiceal Malignancies
  • BRCA gene mutations in cancer
  • Endometriosis Research and Treatment
  • Cancer-related molecular mechanisms research

Frequently publishing in journals such as:

  • Geburtshilfe und Frauenheilkunde
  • International Journal of Gynecological Cancer
  • Gynecologic Oncology
  • Archives of Gynecology and Obstetrics
  • Ovarian Cancer

Some of the recent papers attributed to Andreas du Bois include:

  • Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20., 2020, Journal of Clinical Oncology
  • Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial, 2020, The Lancet Oncology
  • ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors, 2021, International Journal of Gynecological Cancer
  • Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup, 2022, The Lancet Oncology
  • Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update, 2020, International Journal of Gynecological Cancer

Collaborative work is a notable aspect of their research career with frequent co-authors including:

  • Florian Heitz
  • Philipp Harter
  • Beyhan Ataseven
  • Jalid Sehouli
  • Alexander Traut

Best Publications

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

    Andreas du Bois;Hans-Joachim Lück;Werner Meier;Hans-Peter Adams

  • Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

    Jacobus Pfisterer;Marie Plante;Ignace Vergote;Andreas du Bois

  • Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

    Ganna Chornokur;Hui-Yi Lin;Jonathan P. Tyrer;Kate Lawrenson

  • Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

    Gunter von Minckwitz;Andreas du Bois;Marcus Schmidt;Nicolai Maass

  • Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

    Eric Pujade-Lauraine;Uwe Wagner;Elisabeth Aavall-Lundqvist;Val Gebski

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

    Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley

  • Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

    Michael Untch;Peter A. Fasching;Gottfried E. Konecny;Stephan Hasmüller

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group

    Gunter von Minckwitz;Günter Raab;Angelika Caputo;Martin Schütte

  • A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

    Philipp Harter;Jalid Sehouli;Domenica Lorusso;Alexander Reuss

  • Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)

    Gordon J. S. Rustin;Michael Quinn;Tate Thigpen;Andreas du Bois

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

  • Breast cancer in pregnancy: Recommendations of an international consensus meeting

    Frédéric Amant;Sarah Deckers;Kristel Van Calsteren;Sibylle Loibl

  • Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO

    Philipp Harter;Jalid Sehouli;Alexander Reuss;Annette Hasenburg

  • Gynecologic Cancers in Pregnancy: Guidelines of a Second International Consensus Meeting

    Frédéric Amant;Kristel Van Calsteren;Michael J. Halaska;Jos Beijnen

  • Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer

    Helen J. Mackay;Mark F. Brady;Amit M. Oza;Alexander Reuss

  • Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

    Jacobus Pfisterer;Béatrice Weber;Alexander Reuss;Rainer Kimmig

  • Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study

    Gunter von Minckwitz;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

Frequent Co-Authors

Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Graham G. Giles
Graham G. Giles University of Melbourne
Ian G. Campbell
Ian G. Campbell Peter MacCallum Cancer Centre
Jalid Sehouli
Jalid Sehouli Charité - University Medicine Berlin
Susan J. Ramus
Susan J. Ramus University of New South Wales
Daniel W. Cramer
Daniel W. Cramer Brigham and Women's Hospital
Ellen L. Goode
Ellen L. Goode Mayo Clinic
Jenny Chang-Claude
Jenny Chang-Claude German Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare education pathways can open doors to rewarding careers beyond traditional medical school. For those already holding an RN license, affordable rn to bsn programs allow nurses to complete their Bachelor of Science in Nursing online, often at lower tuition rates.

Those interested in advanced practice may consider direct msn programs online, which offer a streamlined route to a Master’s in Nursing for individuals with non-nursing bachelor’s degrees.

If gaining admission is a concern, many students seek out nursing programs with high acceptance rates, which can ease the competitive pressure of launching a nursing career.

For those drawn to supportive healthcare roles, there are also accredited medical billing and coding schools online with financial aid, making entry into administrative healthcare careers both accessible and affordable.

With a range of online degrees and flexible options, there’s a pathway in healthcare for different backgrounds and career goals.

Best Scientists Citing Andreas du Bois

Trending Scientists

Recently Published Articles